EGFR activation up-regulated PD-L1 expression through the ERK1/2/c-Jun pathway in non-small cell lung cancer (NSCLC) [27], and glutamine modulated PD-L1 expression through the EGFR/ERK/c-Jun pathway in kidney cancer [28]. Here, MAPK3 is linked to non-small cell lung carcinoma.